Develop stabilization policies and regulatory interventions that allow pharmaceutical companies to look ahead with serenity. This is one of the objectives of the Pharmaceutical Table which should reopen shortly. The reconfirmed president of Farmindustria confirmed this in an interview with Farmacista33 Massimo Scaccabarozzi (photo). The opportunity to relaunch the "zero-cost program" presented, on the occasion of the re-election, to Institutions and Politics and to address a series of thorny issues for pharmaceutical companies in a period of full-blown crisis. The request for greater stability, a proposal for changes in the governance structure, more support for innovation and the reorganization of the current too fragmented system at regional level are the topics addressed by the president of Farmindustria, who speaks of "confusion and demagoguery" with regard to the affair of anticancer drugs to be borne by patients as a result of the Balduzzi decree, emphasizing how the disparities exist but the responsibilities are not borne by the pharmaceutical industries.
Let's start with pharmaceuticals. The reopening of the table that with the previous government had stopped after only one meeting is imminent.
Great news. The tables have long technical times and the one on pharmaceuticals has already started late. But there are two aspects of great importance: to begin with, the reconfirmation of Undersecretary De Vincenti who will ensure that we don't have to start from scratch. Then there is the willingness given by the minister to participate in the Table, a clear sign of his consideration for the sector. We asked the Government for a control room between the ministries involved to make health policies and industrial growth compatible.
In the meantime, the minister has said enough to linear cuts
Another great news for us. Linear cuts have always penalized us with important losses for the sector. Pharmaceuticals has already been too damaged in the last 10 years.
His reconfirmation comes in a period of full-blown crisis. What is the scenario you are facing and what are the prospects?
Last week's public meeting was an opportunity to present our program to politics and institutions and an opportunity to reiterate what we have been saying for some time: we are a sector with accounts in order. This was confirmed by the Bank of Italy when, in its periodic analysis of the productivity of all the industrial sectors of the country, it underlines how pharmaceuticals has not only held up but is a driving force for the economy. Among the data illustrated by the Bank of Italy, the 3% annual growth of productivity in our sector stands out against a decrease of 0.6% for the industry as a whole. All in the face of a hostile picture with 44 maneuvers in 11 years, 4 of which in 2012 alone, which introduced heavy cuts in pharmaceuticals. Now is the time to relaunch and that's why we present our three-year program at no cost. The hope is to have the opportunity to grow and consolidate in order to remain the driving force of the economy that we have represented up to now.
His report speaks of "changes in the current governance structure". What are you talking about?
We are the only industry that guarantees how much you will spend in the end
